Introduction
Delayed type hypersensitivity (DTH) is an important in vivo manifestation of cell-mediated immune responses [1] [2] [3] . The development of DTH involves recruitment and activation of antigen-specific T cells, synthesis of a cascade of chemotactic and activating cytokines, recruitment of antigennonspecific effector cells, fibrin deposition, and increased vascular permeability. This is followed, similar to other types of inflammatory responses, by translocation of leukocytes, including monocytes, neutrophils and T lymphocytes, from the vascular system, through extracellular tissue barriers, into the site of inflammation [2] [3] [4] . Subendothelial basement membrane (BM) represents the major physical obstacle for leukocyte extravasation and entry into inflammatory sites. BM is a specialized type of the extracellular matrix (ECM), underlying endothelial and epithelial cell layers in all tissues and organs. In the blood vessel wall, BM functions as a scaffold for cellular architecture and integrity of the endothelium. Enzymatic remodeling of the BM barrier is a prerequisite for leukocyte extravasation during inflammation. In addition, BM remodeling allows for the extravasation of plasma macromolecules 3 .
The BM is organized as a structural lattice of characteristic protein and polysaccharide constituents. Heparan sulfate glycosaminoglycan represents the principal polysaccharide participating in BM formation [5] [6] [7] . Heparan sulfate is composed of repeating disaccharide units that form linear chains covalently bound to a core protein 8, 9 . These chains interact through specific attachment sites with the main protein components of BMs, such as collagen IV, laminin and fibronectin. Such interactions make heparan sulfate an essential molecule responsible for the BM barrier function 10 . The mammalian endoglycosidase heparanase is the predominant enzyme that degrades heparan sulfate [11] [12] [13] [14] . Enzymatic cleavage of heparan sulfate results in disassembly of extracellular barriers for cell movement and thus allows for migratory behavior of different cell types in a variety of pathophysiologic conditions, such as morphogenesis, angiogenesis, and cancer only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From metastasis 11, [15] [16] [17] [18] [19] [20] . Possible involvement of heparanase in inflammation has also been addressed 4, 16, 21 , emphasizing the contribution of heparanase residing in activated cells of the immune system 16, [21] [22] [23] [24] . The exact role of heparanase in the inflammatory process remains unclear. Prior to cloning of the heparanase gene it has been shown that inhibition of T lymphocyte derived heparanase by species of heparin inhibits T cell migration and T cell-mediated immunity 21, 22, 25 . The causative involvement of heparanase in this system was, however, questionable because of the multiple biological activities of heparin 26, 27 . In the same time it was reported that degradation products reportedly released by heparanase from the ECM, inhibit DTH reactivity in mice 28 .
Our research was undertaken to elucidate the source and biological significance of heparanase in inflammation. We applied DTH inflammatory model, as well as recently developed in vivo systems for heparanase overexpression 29 , gene silencing 30 and monitoring heparanase promoter activation 31, 32 . Our results reveal that induction of heparanase gene expression in the vascular endothelium is an important parameter of the inflammatory response. Timely action of endothelial heparanase in the course of inflammation emerges as an essential step, allowing for remodeling of the vascular BM, increased vessel permeability, and extravasation of leukocytes and plasma proteins. A marked decrease in DTH was obtained upon local delivery of anti-heparanase siRNA. To our knowledge, this study represents the first successful application of anti-inflammatory therapy based on electroporation-assisted heparanase siRNA delivery in vivo. Given the critical role of heparanase in inflammation and other mechanistically related pathologic processes (i.e., tumor progression, angiogenesis) 11, 30, 33 , the anti-heparanase siRNA delivery approach, developed in our study, might be highly relevant to the design of future therapeutic interventions in these conditions. 
The resulting PCR products were visualized by electrophoresis and ethidium bromide staining, and the intensity of each band was quantified using Scion Image software (Scion, Frederick, MD). If needed, cDNA dilutions were adjusted and L19 RT-PCR products were re-amplified in order to obtain similar intensities for L19 signals with all the samples. The adjusted amounts of cDNA were used for PCR with primers HPU-355 (TTCGATCCCAAGAAGGAATCAAC) and HPL-229 (GTAGTGATGCCATGTAACTGAATC), designed to amplify a 564-bp PCR product specific for human heparanase 11 . Only RNA samples that gave completely negative results in PCR without reverse transcriptase were further analyzed, to rule out the presence of genomic DNA contamination. Results are expressed as band intensity relative to that of L19, and represent the mean ዊSD (error bars) of three independent experiments.
only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From Experimental Animals. Female BALB/c mice were purchased from Harlan Laboratories (Jerusalem, Israel). Heparanase-overexpressing transgenic (hpa-tg) mice in a C57BL/6J genetic background 29 were bred at the animal facility of the Hadassah-Hebrew University Medical Center.
Background genes were tested using C57BL/6J genetic markers. The heparanase transgene was introduced to hpa-tg mice under the actin promoter, to drive overexpression of the heparanase gene in most tissues 29 .
Delayed-Type Hypersensitivity (DTH) assay. DTH reactions were induced in the ear skin of 5-6
week-old female BALB/c mice or in hpa-transgenic (hpa-tg) mice and their wild type counterparts.
Mice were sensitized on the shaved abdominal skin with 100 µl of 2% oxazolone dissolved in acetone/olive oil Center, Jerusalem, Israel). Anti-heparanase siRNA expression vectors were generated as described 30 .
The empty pSUPER vector was used as a control.
For in vivo electroporation, mice were anesthetized and plasmid DNA was intradermally injected with a 0. performed by squeezing the ear between the two plates and applying six pulses of 75 V with a pulse length of 20 msec and interval of 1 second, and polarity reversal after three pulses.
Administration of heparanase enzymatic inhibitor ST1514 in vivo. Heparanase inhibitor ST1514
(52% glycol split non-anticoagulant heparin, H, 52 gs, MW=11,200) [38] [39] [40] was kindly provided by Drs.
Claudio Pisano and Sergio Penco (Sigma-Tau, Pomezia, Rome, Italy). ST1514, or vehicle alone (PBS), were administered intraperitoneally (50 µg/mouse, n=4 mice/group X 2 ears/mice) 1 min prior to challenge with oxazolone and every hour during the following 8 hours of the experiment.
Permeability assay. DTH challenged (n = 5) and untreated (n = 8) mice were injected intravenously with 100 µl Evans blue dye (30 mg/kg in 100 µl PBS (Sigma)) at 16 h after oxazolone challenge. The intensity of vascular permeability was analyzed macroscopically.
Heparanase Activity. Equal protein aliquots of cell lysates from 1 x 10 6 cells were incubated (3 h, 37°C, pH 6.6) in dishes coated with 35 S-labeled ECM, prepared as described 11, 41 . Sulfate-labeled material released into the incubation medium was analyzed by gel filtration on a Sepharose 6B column 41 . Nearly intact heparan sulfate proteoglycans are eluted just after the void volume (peak I, K av < 0.2, fractions 1-10). Heparan sulfate degradation fragments produced by heparanase are eluted later with 0.5<K av <0.8 (peak II, fractions 15-35) 41 . Each experiment was performed at least three times, and the variation in elution positions (Kav values) did not exceed 15% of the mean. Reaction only.
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Luciferase assay. Mice ears were removed just before or 48 h after the DTH challenge with oxazolone. The ears were snap frozen in liquid nitrogen and pulverized to a fine powder with a liquid nitrogen-cooled pestle. The powder was resuspended in 100 µl of ice-cold Reporter Lysis Buffer (Promega Corp., Madison, WI), frozen and thawed 3 times and centrifuged for 20 min at 4 o C at 14,000 rpm. Supernatant was transferred to a new tube, protein content was determined and 25 µl samples were assayed for LUC activity using the Luciferase Reporter Assay system (Promega).
LUC activity was calculated as light units/unit protein, which yields values similar to those based on internal beta-galactosidase transfection standards 42 . Data are presented as the means of at least three determinations, and all experiments were repeated at least twice with similar results.
Results

Association between DTH reactivity and heparanase levels
We first studied the DTH reactivity in homozygous transgenic (hpa-tg) mice overexpressing human heparanase in all tissues 29 . Hpa-tg mice and their wild-type counterparts were sensitized with the hapten oxazolone, as described in Methods, and the DTH reaction was elicited 5 days later by applying oxazolone onto the ears. Twenty-four hours after the oxazolone challenge, a markedly enhanced inflammatory response and edema formation were detected in hpa-tg mice in comparison with wild-type mice, as reflected by a 3.5 fold increase in ear thickness in the hpa-tg mice vs. a 2-fold increase in wild type mice ( Figure 1 ). The differences in the extent of edema formation between the two groups of mice remained statistically significant for 3 days after challenge ( Figure 1 ). These results prompted us to determine the levels of endogenous heparanase during DTH induction in wild type mouse ears. As only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From shown in figure 2B , high levels of the heparanase protein were detected by immunostaining in the ears in which inflammation has been elicited by oxazolone, as compared to low levels or absence of heparanase in control, unchallenged ears ( Figure 2A) . Notably, a greater part of tissue elements expressing elevated levels of heparanase in the dermis of DTH-affected ears was represented by capillary vascular endothelium ( Figure 2B ). In the ears of hpa-tg mice, both prior and post challenge, immunostaining revealed elevated heparanase protein content in epithelial keratinocytes (not shown) and vascular endothelial cells (Figure 2 C, D) . The intensity of heparanase staining in both unchallenged and challenged hpa-tg ears was similar and comparable to that observed in wild type animals following the oxazolone challenge ( Figure 2B ).
Induction of heparanase expression in endothelial cells in vitro by DTH mediator cytokines.
Tumor necrosis factor (TNF ) and interferon (IFN-) are regarded as key mediators of the DTH reaction 3, 43, 44 . Stimulatory effect of TNF on heparanase expression and secretion by the vascular endothelium has been recently reported 45 . We investigated the effect of IFN-on endothelial heparanase expression. For this purpose, we used one of the best characterized vascular endothelial cell line EA.hy926 34, 35 . EA.hy926 cells were treated or untreated with IFN-for 24 hours and then tested for heparanase mRNA expression. Semiquantitative RT-PCR reaction revealed that IFNtreatment yielded a 3-fold increase in heparanase mRNA content, as compared to untreated cells ( Figure 3A ). Treatment with tumor necrosis factor (TNF ), yielded a 2-fold increase in heparanase expression by EA.hy926 cells (not shown), in agreement with the previously reported ability of TNF to augment heparanase expression in other types of endothelial cells 45 . We next determined the levels of heparanase enzymatic activity in EA.hy926 endothelial cells, untreated or treated with IFN-, to verify the RT-PCR observations. Heparanase activity was tested by only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From incubation (3 h, 37°C) of cell lysate samples with a metabolically sulfate-labeled ECM. Sulfatelabeled degradation products released into the incubation medium were subjected to gel filtration on Sepharose 6B columns 11, 41 . The substrate alone consisted almost entirely of nearly intact, highmolecular-weight material eluted just after the void volume (peak I, fractions 1-10, Kav < 0.2). This material (peak I) has been previously shown to be generated by a proteolytic activity residing in the ECM itself and/or expressed by the cells 16 . The elution pattern of labeled material released during incubation of lysed untreated cells with sulfate-labeled ECM, showed little or no heparanase enzymatic activity ( Figure 3B ). In contrast, a high heparanase activity was detected in lysates of IFN-treated cells, as indicated by a 3-4 fold increase in release from ECM of low-molecularweight sulfate-labeled fragments (peak II, fractions 20-35, 0.5 <Kav < 0.8) 11, 41 ( Figure 3B ). These fragments were shown to be degradation products of heparan sulfate, as they were 5-6 fold smaller than intact heparan sulfate side chains, resistant to further digestion with papain and chondroitinase ABC, and susceptible to deamination by nitrous acid 41 .
Heparanase promoter activation during DTH inflammation
In order to test whether heparansase induction during inflammation occurs due to a transcriptional activation of the heparanase gene, we next applied the in vivo electroporation technique, based on injection of the expression vector into the ear, followed by application of an electric field 32, 46 to deliver the LUC reporter gene driven by the heparanase promoter (Hpse-LUC) 31 into the ear, prior to DTH elicitation. Four days following sensitization with oxazolone, the ears of BALB/c mice in the experimental group were electroporated with the Hpse-LUC construct. Ears of mice in the control group were electroporated with construct containing the LUC gene under a constitutive CMV promoter (CMV-LUC) 32 . In an additional control group, ears of mice were electroporated with a construct containing the LUC gene driven by a mutated heparanase promoter, bearing a only.
For Figure   4C ), verifying that the difference observed in the experimental group was heparanase promoterspecific and not due to variation in transfection efficiency. These data indicate that the increase in heparanase levels in DTH inflammation occurs through specific activation of the heparanase gene promoter.
Local silencing of heparanase profoundly decreases inflammatory response in vivo
To explore the effect of local heparanase silencing on DTH reactivity, we delivered anti-mouse heparanase siRNA (pSi2) expression vector 30 to BALB/c mouse ears, 24 hours prior to challenge with the hapten. The design of the pSi2 vector and demonstration of its knock-down effect on mouse heparanase gene expression (80% inhibition) in cultured cells have been previously described by us 30 . In the present study, we applied an in vivo electroporation technique, as described above and in 'Materials & Methods'. To demonstrate that this technique ensures actual only.
For Figure 5C ), using a cooled charged coupled device (CCCD) camera 32 .
In the subsequent set of experiments, 6 week old male BALB/c mice were sensitized with oxazolone and divided into 3 groups (n=5 mice per group) 4 days post sensitization. The first and second groups were electroporated with anti-heparanase siRNA expression vector (pSi2) and with empty vector (pSUPER) 47 , respectively; mice in the third group were not subjected to electroporation. Twenty-four hours later, ears in all three groups were challenged with the hapten.
Hapten was also applied onto the ears of additional 5 mice, which have not been previously sensitized or electroporated, serving as a negative control group. The ear thickness was monitored for 5 consecutive days ( Figure 5A ). Twenty-four hours post challenge, a marked inflammatory response was detected in both the pSUPER-electroporated and non-electroporated ears, reflected by more than a two-fold increase in ear thickness, as compared with the control group. In contrast, in the ears electroporated with the anti-heparanase siRNA encoding vector pSi2, the inflammatory response was significantly inhibited, as noted by a 77% decrease in ear swelling and edema formation, compared to ears electroporated with the pSUPER vector alone ( Figure 5A ). We have previously demonstrated the persistence of heparanase silencing in murine cells in vitro following pSi2 transfection (75% inhibition at 48 hours post transfection and 50% inhibition at 96 hours post transfection). To test inhibitory effect of siRNA silencing in endothelial cells, we determined heparanase activity in human EA.hy926 vascular endothelial cells at various time points after electroporation with the anti-human heparanase siRNA encoding pSH1 vector, analogous to pSi2.
Maximal effect of siRNA silencing (80% inhibition) was observed during the first 72 hours after electroporation and was still pronounced by 96 hours post electroporation (50% inhibition, not only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From shown). To test the local heparanase expression in siRNA-treated skin and to ensure that electroporation of pSi2 resulted in heparanase silencing throughout the in vivo experiment, we compared heparanase immunostaining in tissue sections of the ears in which DTH was induced following electroporation with the pSi2 or pSUPER vectors. Intense heparanase staining was observed in pSUPER-electroporated ears, 48 hours after the challenge (that is 72 hours after electroporation, Figure 5B right), vs. a very weak or no heparanase staining in pSi2-electroporated ears ( Figure 5B left) , similar to heparanase levels observed in normal untreated ears (Figure 2A ).
Decrease in a number of positively-stained cells other than endothelial cells (i.e., epidermal and hair follicle keratinocytes, several dermis-residing cells that may express basal levels of heparanase 32, 39 ) was also found in pSi2-electroporated ears (Fig. 5B left) . Altogether, these results demonstrate that heparanase gene silencing in pSi2-electroporated ears persisted at least for 2 days following the challenge.
We next tested the effect of the potent heparanase enzymatic inhibitor ST1514 (glycol split, nonanticoagulant heparin [38] [39] [40] ) on DTH reactivity. Six week old male BALB/c mice were sensitized with oxazolone and divided into 2 groups (n=4 mice per group X 2 ears) 4 days post sensitization.
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However, attempts to identify the molecular mechanism responsible for increased vascular permeability in DTH inflammation were met with limited success. The data presented in this study directly implicate the heparanase enzyme, locally expressed by the vascular endothelium at the site of inflammation, in degradation of the subendothelial BM and subsequent vascular leakage -a hallmark of delayed hypersensitivity skin reactions 1 .
Mammalian heparanase cleaves heparan sulfate glycosaminoglycans in the BM and other types of ECM 11, 50 . Given the essential role of heparan sulfate chains in preserving the integrity and barrier properties of the BM and ECM [8] [9] [10] 51 , heparanase may adversely affect tissue architecture and play important role in processes that involve ECM disintegration, such as implantation, morphogenesis, angiogenesis, and cancer metastasis 10, 11, 29, 33, 50, 52, 53 .
Less is known about the role of heparanase in inflammation. It was reported that polyanionic compounds known to inhibit heparanase enzymatic activity (e. g., heparin) also inhibit inflammatory responses 21, 25, 54, 55 . Activated T lymphocytes have been viewed as a cellular source of the enzyme in inflammation 16, 21, 22, 24, 55 . On the other hand, it was found that the ability of lympocytes to degrade ECM is inhibited by key inflammatory cytokines 56 .
Here, we demonstrated the induction of locally-expressed heparanase at the site of inflammation in vivo and established its mechanistic involvement in DTH inflammatory reaction. Over-expression of heparanase in a mouse transgenic model significantly enhanced DTH reactivity. Unlike the intensity of the DTH reaction, its time course remained the same in both transgenic and wild-type animals ( Figure 1 ). This suggests that heparanase is primarily involved in the initial stages of the inflammatory response, i.e., increase in vascular permeability, most likely through disruption of the subendothelial BM. By monitoring in vivo activity of luciferase driven by the heparanase gene regulatory sequence, we demonstrated that heparanase promoter activation occurs in the only.
For Local in vivo electroporation of anti-heparanase siRNA into the ear skin markedly inhibited DTH reactivity, demonstrating the decisive involvement of heparanase in inflammation. In order to distinguish between heparanase expressed by local cellular elements at the site of inflammation vs.
the enzyme expressed by circulating immunocytes, the in vivo siRNA experiments were designed to achieve heparanase silencing one day prior to challenge with the hapten. Since T cells, known to mediate DTH response, attach to the vascular endothelium and extravasate toward the hapten only after the challenge 2 , we did not expose the recruited T cells to anti-heparanase siRNA administered by local electroporation executed prior to challenge. The same is correct for any other free circulating cells of the immune system. On the other hand, endothelial cells are present at the only.
For Previously we have shown that heparanase gene silencing approach applied in vitro specifically suppresses invasive and metastatic potential in various tumor models 30 . Thus, in addition to the potential promise for an anti-inflammatory treatment, the specific heparanase siRNA delivery system described in this study will encourage development of novel heparanase-based therapeutic modalities, highly pertinent in other pathological conditions involving undesired heparanase activity, particularly cancer [60] [61] [62] [63] .
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